The researchers discovered that the saliva of hemophilia A patients contains extrinsic tenase complexes, which are located on vesicles. Extrinsic tenase complexes are protein complexes that ...

Among patients with hemophilia who undergo circumcision, a multidisciplinary approach prior to surgery is needed to ensure a successful outcome. The researchers of the current analysis presented the ...

Two new patients in the U.S. have received Hemgenix (etranacogene dezaparvovec), the first gene therapy to be approved for hemophilia B, per new reports. The therapy was first administered last year ...

*Refers to the latest 2 years of omaha.com stories. Cancel anytime. A preview of Nebraska Medicine's Innovation Design Unit in December 2024 After more than four decades of infusing himself with ...

“As the first treatment of its kind for this population, Alhemo represents a significant step in helping to address the unmet needs of patients with hemophilia with inhibitors, highlighting Novo ...

After more than four decades of infusing himself with the blood clotting factor his body can’t make, Chad Stevens decided it was time to try something new. Stevens, 63, suffers from hemophilia B ...

This production improves thrombin generation and clot formation in patients with hemophilia A or B with inhibitors. The approval is supported by data from the multicenter, open-label phase 3 ...

Prophylactic, or preventive, treatment with factor VIII (FVIII) replacement therapy for four years reduced annual bleeding rates by 91% for people with severe hemophilia A, a study from Taiwan ...

About 30% of patients living with severe hemophilia A and 5% to 10% of those with severe hemophilia B develop inhibitors, which often complicates their treatment, according to Novo Nordisk.

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older. The FDA recently approved ...